inclusion criteria: 1. admitted to the hospital with symptoms of covid-19 2. male and females age ≥18 years old 3. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 4. clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 5. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 6. subject (or legally authorized representative) gives written informed consent prior to performing any study procedures 7. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19 2. male and females age ≥18 years old 3. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 4. clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 5. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 6. subject (or legally authorized representative) gives written informed consent prior to performing any study procedures 7. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: admitted to the hospital with symptoms of covid-19 male and females age ≥18 years old laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln subject (or legally authorized representative) gives written informed consent prior to performing any study procedures subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: admitted to the hospital with symptoms of covid-19 male and females age ≥18 years old laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln subject (or legally authorized representative) gives written informed consent prior to performing any study procedures subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19 2. male and females age ≥18 years old 3. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 4. clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 5. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 6. subject (or legally authorized representative) gives written informed consent prior to performing any study procedures 7. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19 2. male and females age ≥18 years old 3. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 4. clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 5. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 6. subject (or legally authorized representative) gives written informed consent prior to performing any study procedures 7. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19 2. male and females age ≥18 years old 3. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 4. clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4 or 5 5. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 6. subject (or legally authorized representative) gives written informed consent prior to performing any study procedures 7. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19 2. male and females age ≥18 years old 3. laboratory confirmed positive sars-cov-2 rtpcr test within 7 days prior to randomization 4. clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4 or 5 5. coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln 6. subject (or legally authorized representative) gives written informed consent prior to performing any study procedures 7. subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study